Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
Ono will have an exclusive option right to discover, develop, and commercialize drug candidates generated by the sequences designed by Jorna worldwide
OSAKA, Japan, April 21, 2025--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") announced that it has entered into a research collaboration agreement with Jorna Therapeutics (Headquarters: Cambridge, Massachusetts, USA; CEO: Chengwei Luo; "Jorna") in December 2024 aimed at drug discovery using Jorna's proprietary ribonucleic acid (RNA) editing platform. Having completed the validation of this platform, Ono has begun the search for nucleic acid sequences that could serve as drug candidates.
Under the agreement, Jorna will design RNA editing drug sequences using its proprietary protein and RNA generative AI model, which is based on the quantum mechanics-based AI called SkyEngine. Ono will have an exclusive option right to discover, develop, and commercialize drug candidates generated by the sequences designed by Jorna worldwide. In addition to the upfront payment already made to Jorna, Ono will also pay for research funding and milestone payments based on the progress of the research.
"We highly value Jorna's unique generative AI technologies, which combine large-scale amino acid sequence information and language models to design desired proteins," said Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research of Ono. "Through this partnership, we aim to accelerate drug development using RNA editing technology and provide new treatment options to patients around the world with unmet medical needs."
"We are delighted to collaborate with Ono to advance our shared vision of delivering groundbreaking therapies to patients. This partnership is expected to accelerate efforts to bring RNA editing-based therapies to market by leveraging Ono's global resources and expertise," said Chengwei Luo, Founder and CEO of Jorna.
About Jorna Therapeutic's RNA Editing PlatformJorna's RNA editing platforms, developed using proprietary protein and RNA generative AI models, can efficiently and safely introduce edits to previously inaccessible target RNAs. The AI technology underpinning this platform, known as SkyEngine, analyzes interatomic interactions within and between proteins and small molecules to identify and design sequences. This allows for the precise design of proteins necessary for highly efficient RNA editing.
About Jorna TherapeuticsJorna is a biotechnology company that develops technologies to introduce mutations into target RNA using multiple approaches. By leveraging its proprietary RNA editing technology, designed through AI models and advanced high-throughput systems, Jorna Inc. aims to provide transformative treatments for patients who previously had no therapeutic options. For more information, please visit the company's website at www.jornatx.com.
About Ono Pharmaceutical Co., Ltd.Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of "Dedicated to the Fight against Disease and Pain," Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421101609/en/
Contacts
Ono Pharmaceutical Co., Ltd.Corporate Communicationspublic_relations@ono-pharma.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
LEWISVILLE, Texas, July 25, 2025--(BUSINESS WIRE)--Caliber Holdings Inc. ("Caliber") today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caliber expects to use the proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. This news release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. View source version on Contacts Media Relations: CaliberPR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
37 minutes ago
- Business Wire
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On July 15, 2025, during market hours, Benzinga published an article entitled 'Simulations Plus Sees Weaker Demand Persist, Outlook Softens.' The article stated that Simulations Plus shares had declined 'following the release of [Simulations Plus'] third-quarter 2025 earnings report.' The article stated that Simulations Plus had reported sales of $20.4 million, representing a 10% year-over-year increase, but this fell short of the consensus estimate of $20.9 million.' Further, '[t]his miss followed preliminary third-quarter sales figures released in June, which were already lower than expectations at $19 million to $20 million, compared to a consensus of $22.78 million.' On this news, the price of Simulations Plus stock fell 25.75% on July 15, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Wire
37 minutes ago
- Business Wire
Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
LEWISVILLE, Texas--(BUSINESS WIRE)--Caliber Holdings Inc. ('Caliber') today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the 'SEC') relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caliber expects to use the proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. This news release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
